X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

June 27, 2019

Industry Trends in Biologic Formulations

In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.
Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Previous Posts
CPhI China Tradeshow

June 20, 2019

West Helps Simplify the Journey™ in China

Jessie Zhang

Jessie Zhang

Manager, Global Communications, AP

SmartDose In-Use

May 07, 2019

The Impact Poor Formulations Have on Drug Development Programs

Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Leo Posner of Johnson & Johnson presenting at the PDA Combo Workshop

April 03, 2019

The Challenges of Combination Products

Fran DeGrazio

Fran DeGrazio

VP, Technical Services and Scientific Affairs

NovaGuard SA Pro Safety System

March 14, 2019

The Importance of Safety Systems and Usability Testing

Jean-Paul Crepel

Jean-Paul Crepel

Sr.Manager, Prod Management, Pre-filled S&D

Various input outline for drug product and user needs

February 18, 2019

How to Optimize Delivery for Drugs Delivered via PFS and Auto-Injector

Royce Brockett

Royce Brockett

Director, Product Management, PFS

PFS Syringe Systems

February 01, 2019

Challenges in Drug Containment and Delivery: How to Qualify Prefillable Solutions

Royce Brockett

Royce Brockett

Director, Product Management, Prefillable Systems

Load more